Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2010-02-17

FDA Approved: AMLODIPINE AND ATORVASTATIN — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental application from Prasco Laboratories to market a generic fixed-dose combination of amlodipine besylate and atorvastatin calcium.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Amlodipine and Atorvastatin (amlodipine besylate and atorvastatin calcium)

Snippet

SUPPL AP for AMLODIPINE AND ATORVASTATIN (AMLODIPINE AND ATORVASTATIN)